Aurobac Therapeutics SAS is a precision medicine biotech company focused on combating antimicrobial resistance using engineered lysin enzymes derived from bacteriophage systems. Established as a joint venture between Boehringer Ingelheim, Evotec, and bioMérieux, Aurobac integrates diagnostics with therapeutic design to target high‑risk Gram‑negative infections such as Pseudomonas aeruginosa and sepsis.
Lysin product pipeline:
- ATX401: Engineered lysin targeting Gram-negative pathogens.
